This schedule helps sustain NAD+ levels, fostering ongoing energy and mental sharpness
Additionally, we stated in the CY 2026 OPPS/ASC proposed rule that we believe that the pass-through payment category C1765 may also appropriately describe the Axoguard HA+ Nerve Protector TM because the device, as described by the applicant, is designed to be placed on and around neural structures to be a protective interface between a nerve and the surrounding tissue, to minimize the potential for soft tissue attachments, and to ensure the nerve's ability to glide through tissue structures during anatomic movement, and therefore may be appropriately described as an adhesion barrier consistent with devices described by C1765
Lacoste C, Avril M, Frassati-Biaggi A, Dupin N, Chrtien-Marquet B, Mah E, et al
Ozempic (semaglutide) functions as a glucagon-like peptide-1 (GLP-1) receptor agonist that slows gastric emptying, increases satiety signals, and improves insulin sensitivity without direct stimulant effects
